Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 1,071,505 | 957,797 | 726,437 | 517,235 | 484,145 |
| Cost of Goods | 88,998 | 81,841 | 41,638 | 10,166 | 19,141 |
| Gross Profit | 982,507 | 875,956 | 684,799 | 507,069 | 465,004 |
| Operating Expenses | 878,694 | 646,003 | 758,816 | 730,831 | 635,584 |
| Operating Income | 104,811 | 230,794 | -73,379 | -223,596 | -170,439 |
| Other Income | 34,093 | 27,281 | 22,343 | 10,152 | 2,920 |
| Pre-tax Income | 138,904 | 258,075 | -51,036 | -213,444 | -167,519 |
| Income Tax | -252,096 | 31,624 | 10,250 | 2,531 | 351 |
| Net Income Continuous | 391,000 | 226,451 | -61,286 | -215,975 | -167,870 |
| Net Income | $391,000 | $226,451 | $-61,286 | $-215,975 | $-167,870 |
| EPS Basic Total Ops | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 |
| EPS Basic Continuous Ops | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 |
| EPS Diluted Total Ops | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 |
| EPS Diluted Continuous Ops | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 |
| EPS Diluted Before Non-Recurring Items | 0.84 | 0.67 | -0.37 | -1.34 | -1.05 |
| EBITDA(a) | $111,147 | $237,373 | $-75,360 | $-224,306 | $-164,691 |